Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/30/11
End: 02/28/14
Due: 02/28/15
Phase: N/A
Priority: Normal
Start: 04/30/10
End: 03/31/11
Due: 03/31/12
Phase: N/A
Priority: Normal
Start: 09/15/23
End: 03/31/27
Due: 03/31/28
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | NCT01290692 | TVAX Biomedical | user2@example.com | None | 2011-06-30 | 2014-02-28 | 2015-02-28 | - | - | 2025-07-14 |
| Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | NCT01081223 | TVAX Biomedical | user2@example.com | None | 2010-04-30 | 2011-03-31 | 2012-03-31 | - | - | 2025-07-14 |
| Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | NCT05685004 | TVAX Biomedical | user2@example.com | None | 2023-09-15 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |
| TVI-Brain-1 in Expanded Access Patient | NCT05936216 | TVAX Biomedical | user2@example.com | None | - | - | - | - | - | 2025-07-14 |